Muaz Alsabbagh, MD1, Khaled Alsabbagh Alchirazi, MD2, Ahmed El Telbany, MD, MPH3, Maysarah Jamil. Qapaja, MS4, Mounir Ibrahim, MD5, Miguel D Regueiro, MD1 1Cleveland Clinic, Cleveland, OH; 2Aurora Healthcare, Brookfield, WI; 3University of New Mexico, Albuquerque, NM; 4Cairo University School of Medicine, Cairo, Al Jizah, Egypt; 5Cleveland Clinic Foundation, Holmdel, NJ
Introduction: Janus Kinase Inhibitors (JAKi) have shown highly effective treatment for IBD patients. There have been several reports that JAKi might significantly increase the risk of infections. We aim to investigate the risk of infection in IBD patients treated with JAKi.
Methods: We conducted a five-year study using TriNetX data from (2018 to 2023) to examine patients diagnosed with IBD. We compared patients who received JAKi therapy to those who did not. To ensure comparable groups, we matched patients based on age, gender, race, ethnicity, existing health conditions and IBD related medications. We assessed IBD-related outcomes and infection rates at 6 months, 1 year, and 3 years after starting treatment. We used adjusted odds ratios (aOR) with 95% confidence intervals (CI) to measure the impact of JAKi on infection outcomes.
Results: After score matching, our study included 5,551 IBD patients in both cohorts. Compared to IBD patients not on JAKi, we found that IBD patients on JAKi had lower rates urinary tract infection (aOR = 0.71, 95% CI = 0.56, 0.89), acute upper respiratory infections (aOR = 0.78, [0.52, 1.18]), and cellulitis (aOR =0.62, [0.40, 0.97] at 6 months and 3 years. When compared to IBD patients not on JAKi, the only infection that we found at a higher rate in IBD patients on JAKi was herpes zoster at 6 months, 1 year, and 3 years, Table1.
Discussion: IBD patients treated with JAKi had lower rates of most infections compared with IBD patients not receiving JAKi. The one notable exception was a higher rate of herpes zoster in IBD patients treated with JAKi. Our study provides real world data that are consistent with the clinical trial results and confirms the importance of herpes zoster vaccination for IBD patients administered JAKi.
Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
Disclosures:
Muaz Alsabbagh indicated no relevant financial relationships.
Khaled Alsabbagh Alchirazi indicated no relevant financial relationships.
Ahmed El Telbany indicated no relevant financial relationships.
Maysarah Qapaja indicated no relevant financial relationships.
Mounir Ibrahim indicated no relevant financial relationships.
Miguel D Regueiro: AbbVie – Advisory Committee/Board Member, Consultant, Speakers Bureau.
Muaz Alsabbagh, MD1, Khaled Alsabbagh Alchirazi, MD2, Ahmed El Telbany, MD, MPH3, Maysarah Jamil. Qapaja, MS4, Mounir Ibrahim, MD5, Miguel D Regueiro, MD1. P2662 - Increased Herpes Zoster Rates, but Not Other Infections, in IBD Patients Treated With JAK Inhibitors: A Multi-Center 5-Year Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
